Search

Search Constraints

You searched for: Author/Creator Staehler, Michael

Search Results

1. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Issue 10189 (15th June 2019)

2. 19 Stereotactic Body Radiotherapy for Large Primary Large Renal Cell Carcinoma: A Report from the International Radiosurgery Oncology Consortium for Kidney (IROCK). (October 2019)

3. First‐line pazopanib in intermediate‐ and poor‐risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial. Issue 4 (18th August 2020)

4. Consensus statement from the International Radiosurgery Oncology Consortium for Kidney for primary renal cell carcinoma. (March 2016)

5. Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study. (2nd January 2022)

6. Everolimus after failure of one prior VEGF‐targeted therapy in metastatic renal cell carcinoma: Final results of the MARC‐2 trial. Issue 7 (26th October 2020)

7. 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney). Issue 12 (December 2022)

10. 44: Long-Term Outcomes of SABR to Primary Renal Cell Carcinoma: A Multi-Centre Analysis from the International Radiosurgery Oncology Consortium for Kidney (IROCK). (September 2022)